secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0000200406-23-000109
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ completes Laminar acquisition for $400M upfront; cuts FY2023 adjusted EPS guidance by $0.17
--------------------------------------------------------------------------------

- Upfront payment of $400M (subject to adjustments) plus potential clinical/regulatory milestone payments.
- Laminar's LAAX device uses rotational motion to eliminate left atrial appendage; FDA approved U.S. pivotal study starting in early 2024.
- FY2023 adjusted operational EPS guidance revised to $9.85-$9.91; reported to $9.90-$9.96, reflecting $0.17 IPR&D charge.
- Acquisition expected to reduce FY2024 EPS by approximately $0.15.
- Biosense Webster (JNJ MedTech) will integrate Laminar; targets ~38M AFib patients worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000109/0000200406-23-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040623000109/jnj-20231130.htm
  HTML page:      https://secwatch.observer/filing/0000200406-23-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer